|
|
|
Volumn 23, Issue 149, 2014, Pages 117-120
|
|
In obesity: Unacceptable risks
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GLYCOSYLATED HEMOGLOBIN;
LORCASERIN;
PLACEBO;
ANTIOBESITY AGENT;
BENZAZEPINE DERIVATIVE;
ARTICLE;
ASTROCYTOMA;
BODY WEIGHT;
BREAST CANCER;
CLINICAL EVALUATION;
CONSTIPATION;
CONTROLLED CLINICAL TRIAL (TOPIC);
DEPRESSION;
DIZZINESS;
DRUG ABUSE;
DRUG INDUCED HEADACHE;
DRUG INTERACTION;
DRUG WITHDRAWAL;
EMOTIONAL DISORDER;
EUPHORIA;
EUROPEAN UNION;
EXERCISE;
FATIGUE;
FOLLOW UP;
HEART VALVE;
HEMOGLOBIN BLOOD LEVEL;
HUMAN;
INCIDENCE;
LIVER METABOLISM;
NAUSEA;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OBESITY;
PREGNANCY;
RISK FACTOR;
SUICIDE;
TREATMENT WITHDRAWAL;
UNITED STATES;
VALVULAR HEART DISEASE;
WEIGHT GAIN;
WEIGHT REDUCTION;
XEROSTOMIA;
CLINICAL TRIAL (TOPIC);
DRUG APPROVAL;
DRUG EFFECT;
METHODOLOGY;
ANTI-OBESITY AGENTS;
BENZAZEPINES;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
HUMANS;
OBESITY;
OVERWEIGHT;
WEIGHT LOSS;
|
|
EID: 84902154768
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (11)
|
|
References (11)
|
